Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Reata Pharma (RETA)

28.74   0.61 (2.17%) 01-16 05:29
Open: 27.8 Pre. Close: 28.13
High: 28.88 Low: 27.24
Volume: 393,889 Market Cap: 1,046M
Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease (CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct Phase II study for various form of CKD, such as IgA nephropathy, type 1 and type 2 diabetic CKD, hypertensive CKD, focal segmental glomerulosclerosis, and others. It is also developing RTA 901 for neurological diseases; and RTA 1701 for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of autosomal dominant polycystic kidney disease. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Plano, Texas.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 28.921 - 29.083 29.083 - 29.231
Low: 26.825 - 27.031 27.031 - 27.219
Close: 28.43 - 28.74 28.74 - 29.024

Technical analysis

as of: 2022-01-15 8:49:19 PM
Stoxline posted a BUY today, upgraded from lower rating. Upward movement to be expected.
Target: Six months: 37.19     One year: 43.44
Support: Support1: 27.63    Support2: 25.02
Resistance: Resistance1: 31.84    Resistance2: 37.19
Pivot: 27.89
Moving Average: MA(5): 28.65     MA(20): 28.04
MA(100): 80.15     MA(250): 101.97
MACD: MACD(12,26): -6.71     Signal(9): -9.03
Stochastic oscillator: %K(14,3): 50.44     %D(3): 53.26
RSI: RSI(14): 32.10
52-week: High: 153.41  Low: 25.02  Change(%): -74.1
Average Vol(K): 3-Month: 85242  10-Days: 71642

Price, moving averages and Bollinger Bands

Price and moving averages has closed above its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
RETA has closed below upper band by 33.5%. Bollinger Bands are 78% narrower than normal. The narrow width of the bands suggests low volatility as compared to RETA's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.

Headline News

Tue, 11 Jan 2022
Reata Pharmaceutical's build-to-suit HQ at 6100 Legacy Drive hits sublease market, according to sources - Dallas Business Journal - Dallas Business Journal

Fri, 07 Jan 2022
Woodstock Corp Buys Amgen Inc, Applied Materials Inc, FedEx Corp, Sells Reata Pharmaceuticals ... - Yahoo Finance

Tue, 04 Jan 2022
Bronstein, Gewirtz & Grossman, LLC Reminds Reata Pharmaceuticals, Inc. (RETA) Shareholders of Class Action and Encourages Investors to Contact the Firm - Business Wire

Mon, 03 Jan 2022
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Reata Pharmaceuticals, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 18, 2022 - RETA - PRNewswire

Mon, 03 Jan 2022
RETA INVESTOR FRAUD: Hagens Berman, National Trial Attorneys, Encourages Reata Pharmaceuticals, Inc. (RETA) Investors to Contact Firm's Attorneys, Securities Fraud Class Action Pending - GlobeNewswire

Fri, 31 Dec 2021
Reata's Advisory Committee Hiccup Ruins Its Future Prospects - Seeking Alpha

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Price to Book Value: Outperform Discounted cash flow: Outperform
Return on Assets: Neutral Price to Earnings: Underperform
Return on Equity: Underperform Debt to Equity: Outperform
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 31
Shares Float (M) 30
% Held by Insiders 4.74
% Held by Institutions 85.89
Shares Short (K) 4,220
Shares Short P. Month (K) 4,080

Stock Financials

EPS -7.740
EPS Est This Year -1.760
EPS Est Next Year -2.200
Book Value (p.s.) 7.030
Profit Margin
Operating Margin -1651.90
Return on Assets (ttm) -21.1
Return on Equity (ttm) -125.7
Qtrly Rev. Growth 427.6
Gross Profit (p.s.) -4.768
Sales Per Share 0.437
EBITDA (p.s.) -7.180
Qtrly Earnings Growth
Operating Cash Flow (M) -158
Levered Free Cash Flow (M) -8

Stock Valuations

PE Ratio -3.71
PEG Ratio
Price to Book value 4.09
Price to Sales 65.78
Price to Cash Flow -5.73

Stock Dividends

Forward Dividend
Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2020 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.